CMC And Clinical Strategies For The Successful Development Of Injectable And Oral Peptide Drugs

In this session, Chief Scientific Officer Dr. Andy Lewis delves into the key drivers shaping peptide drug development and explores innovative delivery options to enhance therapeutic outcomes.

By viewing the presentation, attendees will gain valuable insights into clinical strategies for transitioning delivery routes from intravenous (IV) to subcutaneous administration and approaches to strategically phase Chemistry, Manufacturing, and Controls (CMC) investment to minimize risk while meeting the Target Product Profile. The session also highlights critical CMC and clinical lessons learned from over 14 oral peptide programs evaluating 10 different permeation enhancers.

Additionally, participants will discover how Physiologically Based Pharmacokinetic (PBPK) modeling can inform oral peptide development and learn about the role of rapid clinical pharmacokinetic prototyping in optimizing peptide drug formulations. Don’t miss this opportunity to deepen your understanding of cutting-edge strategies in peptide drug development.